{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:37:28Z","timestamp":1792802248298,"version":"4.5.0"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Maxigen Biotech Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["CARTILAGE"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety and clinical performance of a high-purity, non\u2013cross-linked 1.0% sodium hyaluronate administered via intra-articular injection in patients with symptomatic knee osteoarthritis (OA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This 30-week, single-center, open-label post-market clinical performance evaluation enrolled adults with radiographically confirmed knee OA. Participants received five weekly intra-articular injections of 1.0% sodium hyaluronate. Resting pain (VAS), Kellgren\u2013Lawrence (KL) grade, and patient satisfaction were assessed through Week 30, and adverse events were monitored throughout.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean VAS pain scores decreased by 48.3% at Week 8 and 42.8% at Week 30 compared with baseline (both\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001). KL grades were generally stable over time, with no clear radiographic worsening observed during follow-up. Approximately 90% of patients reported satisfaction with treatment, and no treatment-related serious adverse events occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Five weekly intra-articular injections of 1.0% sodium hyaluronate were well tolerated and were associated with reductions in resting pain and stable radiographic findings over 30 weeks, supporting its role as a well-tolerated viscosupplementation option in routine clinical care for knee OA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/19476035261493633","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:30:25Z","timestamp":1792517425000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Evaluation of Repeated Intra-articular 1.0% Sodium Hyaluronate Injections for Knee Osteoarthritis: A 30-Week Post-market Clinical Performance Study"],"prefix":"10.1177","author":[{"given":"Tsu-Te","family":"Yeh","sequence":"first","affiliation":[{"name":"Tri-Service General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"Maxigen Biotech Inc"},{"name":"."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Hsiang","family":"Lin","sequence":"additional","affiliation":[{"name":"Maxigen Biotech Inc"},{"name":"."},{"name":"TCI Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Fu","family":"Chiang","sequence":"additional","affiliation":[{"name":"TCI Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6729-9946","authenticated-orcid":false,"given":"Yi-Wen","family":"Mao","sequence":"additional","affiliation":[{"name":"TCI Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2019.10.007"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216515"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.04.008"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-56665-3"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/19476035241271970"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/1947603517749919"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-015-0775-z"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14082547"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.20986\/resed.2021.3903\/2021"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1231"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41142"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780340704"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2011.11.064"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.04.011"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-017-1084-9"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/11632580-000000000-00000"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00450-z"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-069722"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2019.06.011"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-025-08875-7"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S485295"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7176.116232"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200108)45"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00523-9"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/1947603519888783"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/1947603520905113"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.3928\/01477447-20250715-01"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.blo.0000143804.26638.82"}],"container-title":["CARTILAGE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19476035261493633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/19476035261493633","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/19476035261493633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:46:26Z","timestamp":1792799186000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/19476035261493633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":28,"alternative-id":["10.1177\/19476035261493633"],"URL":"https:\/\/doi.org\/10.1177\/19476035261493633","relation":{},"ISSN":["1947-6035","1947-6043"],"issn-type":[{"value":"1947-6035","type":"print"},{"value":"1947-6043","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"article-number":"19476035261493633"}}